Xuehui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xuehui Liu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Liheng Guo
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
2 shared publications - Lu Jiang
The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
2 shared publications - Shuai Mao
Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, The 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China
2 shared publications - Tian Zuo
Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, The 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China; The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
2 shared publications - Xin Yin
Department of Critical Care Medicine, Guangdong Provincial Hospital of Chinese Medicine, The 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China
2 shared publications - Chun-Yan Xu
Department of Endocrinology, Wuhan General Hospital of Guangzhou Military Command, 627 Wuluo Road, Wuhan, China
1 shared publication
Latest Publications
- 1 December 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 224, 286-294
Hyperuricemia and contrast-induced acute kidney injury: A systematic review and meta-analysis
- 1 December 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 224, 286-294
Hyperuricemia and contrast-induced acute kidney injury: A systematic review and meta-analysis
- Open Access
- 28 October 2016
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 16 (1) , 1-10
Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies
Hyperuricemia may be associated with an increased risk of coronary heart disease (CHD) mortality; however, the results from prospective studies are conflicting. The objective of this study was to assess the association between hyperuricemia and risk of CHD mortality by performing a meta-analysis. Pubmed and Embase were searched for relevant prospective cohort studies published until July 2015. Studies were included only if they reported data on CHD mortality related to hyperuricemia in a general population. The pooled adjusted relative risk (RR) was calculated using a random-effects model. A total of 14 studies involving 341 389 adults were identified. Hyperuricemia was associated with an increased risk of CHD mortality (RR: 1.14; 95 % CI: 1.06–1.23) and all-cause mortality (RR: 1.20; 95 % CI: 1.13–1.28). For each increase of 1 mg/dl of serum uric acid (SUA), the overall risks of CHD and all-cause mortality increased by 20 and 9 %, respectively. According to the gender subgroup analyses, hyperuricemia increased the risk of CHD mortality in women (RR: 1.47; 95 % CI: 1.21–1.73) compared to men (RR: 1.10; 95 % CI: 1.00–1.19). The risk of all-cause mortality was greater in women. Hyperuricemia may modestly increase the risk of CHD and all-cause mortality. Future research is needed to determine whether urate–lowering therapy has beneficial effects for reducing CHD mortality.
- 28 October 2016
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 16 (1) , 1-10
Open AccessHyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies
Hyperuricemia may be associated with an increased risk of coronary heart disease (CHD) mortality; however, the results from prospective studies are conflicting. The objective of this study was to assess the association between hyperuricemia and risk of CHD mortality by performing a meta-analysis. Pubmed and Embase were searched for relevant prospective cohort studies published until July 2015. Studies were included only if they reported data on CHD mortality related to hyperuricemia in a general population. The pooled adjusted relative risk (RR) was calculated using a random-effects model. A total of 14 studies involving 341 389 adults were identified. Hyperuricemia was associated with an increased risk of CHD mortality (RR: 1.14; 95 % CI: 1.06–1.23) and all-cause mortality (RR: 1.20; 95 % CI: 1.13–1.28). For each increase of 1 mg/dl of serum uric acid (SUA), the overall risks of CHD and all-cause mortality increased by 20 and 9 %, respectively. According to the gender subgroup analyses, hyperuricemia increased the risk of CHD mortality in women (RR: 1.47; 95 % CI: 1.21–1.73) compared to men (RR: 1.10; 95 % CI: 1.00–1.19). The risk of all-cause mortality was greater in women. Hyperuricemia may modestly increase the risk of CHD and all-cause mortality. Future research is needed to determine whether urate–lowering therapy has beneficial effects for reducing CHD mortality.
- Open Access
- 16 April 2014
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 14 (1) , 52
Efficacy of N-acetylcysteine in preventing atrial fibrillation after cardiac surgery: a meta-analysis of published randomized controlled trials
Atrial fibrillation is a common complication after cardiac surgery. The aim of this study is to evaluate whether N-acetylcysteine (NAC) could prevent postoperative atrial fibrillation (POAF).
- 16 April 2014
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 14 (1) , 52
Open AccessEfficacy of N-acetylcysteine in preventing atrial fibrillation after cardiac surgery: a meta-analysis of published randomized controlled trials
Atrial fibrillation is a common complication after cardiac surgery. The aim of this study is to evaluate whether N-acetylcysteine (NAC) could prevent postoperative atrial fibrillation (POAF).